Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Athersys Inc (NASDAQ:ATHX)

1.61
Delayed Data
As of 4:14pm ET
 +0.01 / +0.63%
Today’s Change
0.97
Today|||52-Week Range
2.90
+56.31%
Year-to-Date
Roche Presents Positive Follicular Lymphoma Data on Gazvya
Dec 06 / Zacks.com - Paid Partner Content
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
Nov 30 / Zacks.com - Paid Partner Content
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
Dec 06 / Zacks.com - Paid Partner Content
Epizyme Tazemetostat Gets Fast Track Designation in U.S.
Nov 29 / Zacks.com - Paid Partner Content
Foamix Completes Enrolment in Phase III Acne Drug Studies
Nov 30 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close1.60
Today’s open1.60
Day’s range1.59 - 1.65
Volume381,512
Average volume (3 months)364,464
Market cap$136.8M
Dividend yield--
Data as of 4:14pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+35.48%
Earnings growth (this year)+5.00%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+636.17%
P/E ratioNM
Price/Sales7.14
Price/Book6.79

Competitors

 Today’s
change
Today’s
% change
RGLSRegulus Therapeutics...-0.10-3.85%
AKAOAchaogen Inc+0.22+4.37%
XENEXenon Pharmaceutical...+0.20+2.56%
CTICCTi Biopharma Corp+0.01+1.17%
Data as of 4:00pm ET, 12/09/2016

Financials

Next reporting dateMarch 16, 2017
EPS forecast (this quarter)-$0.08
Annual revenue (last year)$11.9M
Annual profit (last year)-$16.4M
Net profit margin-137.45%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Gil van Bokkelen
President, Chief Operating Officer &
Secretary
William B. J. Lehmann
Corporate headquarters
Cleveland, Ohio

Forecasts


Search for Jobs